当前位置: 首页 >> 检索结果
21. Memantine for Premature Atrial Contractions: A Phase 2 Randomized Clinical Trial.
作者: Yunli Shen.;Chunyu Zeng.;Yingxian Sun.;Jian'an Wang.;Bo Yu.;Xiang Cheng.;Xiaogang Guo.;Dao Wen Wang.;Yue Li.;Wei Han.;Bingqing Zhou.;Hongzhuan Sheng.;Zhaoqi Huang.;Yigang Li.;Guosheng Fu.;Jidong Zhang.;Duanyang Xie.;Dandan Liang.;Yi Liu.;Bing Yang.;Qi Zhang.;Ran Duan.;Hongxiao Li.;Baowei Zhang.;Yizhang Wu.;Liang Zheng.;Jia He.;Shenglin Liu.;Dechun Yin.;Guozhe Sun.;Shu Zhang.;Xiaofan Guo.;Min Zhang.;Yiyi Wang.;Xiajun Hu.;Jing Zeng.;Xiaoli Yang.;Shufeng Li.;Ning Li.;Feng Hu.;Haifeng Wang.;Xinyang Hu.;Yaping Wang.;Cong Zeng.;Kai Wang.;Jian Yang.;Yan Wang.;Jinsheng Lai.;Luyun Wang.;Ke Xiong.;Guanghua Wang.;Qicheng Zou.;Beihua Shao.;Zhiwen Chen.;Yahan Wu.;Junwei Leng.;Jun Pu.;Changsheng Ma.;Yi-Han Chen.
来源: Circulation. 2026年153卷16期1196-1209页
Premature atrial contractions (PACs) are independently associated with atrial fibrillation, stroke, and heart failure, yet no pharmacological therapy is approved for PAC suppression. Experimental studies have identified a functional cardiac glutamatergic system in which N-methyl-D-aspartate receptors regulate atrial electrophysiology. Preclinical studies show that pharmacological antagonism of N-methyl-D-aspartate receptors with memantine suppresses atrial arrhythmias.
22. Clopidogrel Versus Aspirin Monotherapy Beyond 1 Year After PCI: The Final 5-Year Results of the STOPDAPT-2 ACS and STOPDAPT-2 Total Cohort.
作者: Hirotoshi Watanabe.;Takeshi Morimoto.;Masahiro Natsuaki.;Ko Yamamoto.;Yuki Obayashi.;Ryusuke Nishikawa.;Tomoya Kimura.;Kazuaki Imada.;Satoru Suwa.;Tsuyoshi Isawa.;Kenji Ando.;Takanari Fujita.;Kazushige Kadota.;Hideo Tokuyama.;Hiroki Sakamoto.;Hiroshi Suzuki.;Kohei Wakabayashi.;Koh Ono.;Fujio Hayashi.;Kengo Tanabe.;Masaharu Akao.;Yuko Onishi.;Ruka Yoshida.;Takanori Kusuyama.;Toshihiro Tamura.;Yoshiro Onoue.;Masahiro Yagi.;Kazuaki Kaitani.;Takeshi Kimura.; .
来源: Circ Cardiovasc Interv. 2026年19卷6期e016280页
Clopidogrel may have ischemic benefit over aspirin as long-term monotherapy in patients receiving percutaneous coronary intervention.
23. Low-Dose Rivaroxaban Plus Aspirin in Patients With PAD Undergoing Lower Extremity Revascularization With and Without History of Prior Limb Revascularization: Insight From the VOYAGER-PAD Trial.
作者: Mario Enrico Canonico.;Jessica Parr.;E Sebastian Debus.;Mark R Nehler.;Manesh R Patel.;Sonia S Anand.;Mark Svet.;Connie N Hess.;Warren H Capell.;Joseph Ycas.;Julian Chen.;Michael Szarek.;Eva Muehlhofer.;Lloyd P Haskell.;Scott D Berkowitz.;Rupert M Bauersachs.;Marc P Bonaca.
来源: Circ Cardiovasc Interv. 2026年19卷5期e015229页
Patients with peripheral artery disease (PAD) undergoing lower extremity revascularization (LER) are at high risk of major adverse limb events (MALE) and major adverse cardiovascular events. The VOYAGER-PAD trial (Vascular Outcomes Study of Acetylsalicylic Acid Along With Rivaroxaban in Endovascular or Surgical Limb Revascularization for Peripheral Artery Disease) demonstrated that rivaroxaban 2.5 mg twice daily on top of antiplatelet therapy significantly reduced this risk. Whether the risk of major adverse cardiovascular events and MALE and the effect of rivaroxaban are consistent in patients with a history of prior LER versus those without has not been described.
24. NURSE-Led Care in Patients Undergoing Catheter Ablation for Atrial Fibrillation: The NURSECAT-AF Randomized Trial.
作者: Alba Cano-Valls.;Maria Antonia Martinez Monblan.;Esther Carro-Fernández.;Mireia Niebla.;Rebeca Domingo.;Sara Hevia-Puyo.;Montserrat Venturas-Nieto.;Roger Borras.;José María Tolosana.;Andreu Porta-Sánchez.;Jean-Baptiste Guichard.;Till F Althoff.;Ivo Roca-Luque.;Lluis Mont.;Eduard Guasch.
来源: Circ Arrhythm Electrophysiol. 2026年19卷3期e014149页
Atrial fibrillation (AF) is associated with reduced quality of life and frequent hospitalizations. Integrated nurse-led care (NLC) has proven beneficial in unselected AF patients, but evidence specific to patients undergoing catheter ablation is limited. We aimed to assess the impact of a structured nurse-led intervention in patients undergoing first-time AF ablation.
25. Spontaneous Myocardial Infarction After Left Main Revascularization: The EXCEL Trial.
作者: Mahesh V Madhavan.;John Gregson.;Bjorn Redfors.;Shmuel Chen.;Joseph F Sabik.;Akiko Fujino.;Lak N Kotinkaduwa.;Dimitri Karmpaliotis.;Jeffrey W Moses.;Ori Ben-Yehuda.;Patrick W Serruys.;Stuart Pocock.;A Pieter Kappetein.;Akiko Maehara.;Gregg W Stone.
来源: Circulation. 2026年153卷12期890-901页
Limited data are available regarding the relative rates, etiology, and long-term prognostic implications of spontaneous myocardial infarction (MI) after percutaneous coronary intervention (PCI) versus coronary artery bypass graft (CABG) surgery for left main coronary artery disease (LMCAD).
26. Integrative Proteomic and Lipidomic Analysis of Patients With Acute Myocardial Infarction Treated With PCSK9 Antibodies and Statins.
作者: Lukas E Schmidt.;Sean A Burnap.;Bhawana Singh.;Kaloyan Takov.;Sylvain Losdat.;Lore Schrutka.;Lukas Galli.;Konstantinos Theofilatos.;Georg W Otto.;Christian Hengstenberg.;Ioanna Tzoulaki.;Irene M Lang.;Konstantinos C Koskinas.;Walter S Speidl.;Lorenz Räber.;Manuel Mayr.
来源: Circ Genom Precis Med. 2026年19卷2期e005345页
PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibition is a potent cholesterol-lowering strategy. This study examined the effects of PCSK9 monoclonal antibodies (mAbs) and high-intensity statins beyond low-density lipoprotein cholesterol reduction, which are not fully defined, particularly in patients with acute myocardial infarction (MI).
27. Incidence, Risk Factors, and Outcomes in Stressor-Associated Atrial Fibrillation: Insights From the VITAL-AF Trial.
作者: Julian S Haimovich.;Shinwan Kany.;Yuchiao Chang.;Leila H Borowsky.;David D McManus.;Steven J Atlas.;Daniel E Singer.;Steven A Lubitz.;Patrick T Ellinor.;Shaan Khurshid.
来源: Circulation. 2026年153卷6期367-378页
Stressor-associated atrial fibrillation (AF), defined as newly diagnosed AF in the setting of a reversible physiological stressor, is common. However, risk factors, outcomes, and current management practices remain poorly understood.
28. Balloon- Versus Self-Expanding Transcatheter Valves for Failed Small Surgical Aortic Bioprostheses: 3-Year Results of the LYTEN Trial.
作者: Pedro Cepas-Guillén.;Amr E Abbas.;Vicenç Serra.;Victoria Vilalta.;Luis Nombela-Franco.;Ander Regueiro.;Karim M Al-Azizi.;Ayman Iskander.;Lenard Conradi.;Jessica Forcillo.;Scott Lilly.;Álvaro Calabuig.;Eduard Fernandez-Nofrerias.;Siamak Mohammadi.;Carlos Giuliani.;Emilie Pelletier-Beaumont.;Philippe Pibarot.;Josep Rodés-Cabau.
来源: Circ Cardiovasc Interv. 2026年19卷3期e016255页
Data comparing valve systems in the valve-in-valve transcatheter aortic valve replacement (TAVR) field have been obtained from retrospective studies. This prespecified secondary analysis of the LYTEN randomized trial (Comparison of the Balloon-Expandable Edwards Valve and Self-Expandable CoreValve Evolut R or Evolut PRO System for the Treatment of Small, Severely Dysfunctional Surgical Aortic Bioprostheses) aims to compare the 3-year hemodynamic performance and clinical outcomes between balloon-expandable valves (BEV) SAPIEN 3/ULTRA (Edwards Lifesciences) and self-expanding valves (SEV) Evolut R/PRO/PRO+ (Medtronic) in valve-in-valve TAVR.
29. Finerenone, Liver Biomarkers, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: An Analysis of FINEARTS-HF.
作者: Jawad H Butt.;Alasdair D Henderson.;Pardeep S Jhund.;Brian L Claggett.;Akshay S Desai.;Maria Borentain.;Katja Rohwedder.;Rania Dayoub.;Yoriko De Sanctis.;Carolyn S P Lam.;Michele Senni.;Sanjiv J Shah.;Adriaan A Voors.;Johann Bauersachs.;Cândida Fonseca.;Gerard C M Linssen.;Mark C Petrie.;Morten Schou.;Subodh Verma.;Faiez Zannad.;Bertram Pitt.;Muthiah Vaduganathan.;Scott D Solomon.;John J V McMurray.
来源: Circ Heart Fail. 2026年19卷2期e013201页
The prevalence and prognostic significance of liver biomarkers in heart failure (HF) with mildly reduced or preserved ejection fraction are uncertain, with both potential hemodynamic and metabolic contributions to liver dysfunction in these patients. We evaluated the prevalence and prognostic value of liver biomarkers and assessed the effects of the nonsteroidal mineralocorticoid receptor antagonist finerenone on these biomarkers and clinical outcomes in FINEARTS-HF (Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure).
30. Dynamic Change of Coronary Artery Geometry After Bioadaptor Implantation: A Single-blind Randomized Controlled Trial.
作者: Cheng-Hsuan Tsai.;Han-Hsuan Chu.;Ching-Chang Huang.;Chih-Fan Yeh.;Ying-Hsien Chen.;Mao-Shin Lin.;Tsung-Yu Ko.;Chun-Kai Chen.;Yu-Cheng Huang.;Pin-Yi Chiang.;Wen-Jeng Lee.;Hsien-Li Kao.
来源: Circ Cardiovasc Interv. 2026年19卷2期e016191页
The DynamX bioadaptor, a novel coronary implant, is designed to restore vessel function when the thin polymer coating covering the helical strands resorbs 6 months post-percutaneous coronary intervention. We aimed to evaluate vessel conformability 1 year after percutaneous coronary intervention with the bioadaptor, compared with conventional drug-eluting stents (DESs).
31. Association Between the 2022 AHA/ACC/HFSA Heart Failure Staging and Cardiovascular and Kidney Outcomes in Patients With Diabetes and Kidney Disease: A Post Hoc Analysis of the SCORED Randomized Controlled Trial.
作者: Ayodele Odutayo.;Deepak L Bhatt.;Vikas S Sridhar.;Michael Szarek.;Christopher P Cannon.;Lawrence A Leiter.;Darren K McGuire.;Julia B Lewis.;Renato D Lopes.;Benjamin M Scirica.;Kausik K Ray.;Michael J Davies.;Phillip Banks.;Manon Girard.;Subodh Verma.;Jacob A Udell.;Bertram Pitt.;Ph Gabriel Steg.;David Z I Cherney.
来源: Circ Heart Fail. 2026年19卷3期e013054页
The 2022 American Heart Association/American College of Cardiology/Heart Failure Society of America heart failure (HF) classification incorporates cardiac biomarkers to identify early risk of HF. The HF stages may also guide the prognosis and management of cardiovascular and kidney-related events.
32. Delay From First Symptoms in Patients Presenting With STEMI and Cardiogenic Shock: Insights From the DanGer Shock Trial.
作者: Lisette Okkels Jensen.;Rasmus Paulin Beske.;Hans Eiskjær.;Norman Mangner.;Amin Polzin.;P Christian Schulze.;Carsten Skurk.;Peter Nordbeck.;Peter Clemmensen.;Vasileios Panoulas.;Sebastian Zimmer.;Andreas Schäfer.;Nikos Werner.;Lene Holmvang.;Kristian Wachtell.;Thomas Engstøm.;Nanna Louise Junker Udesen.;Henrik Schmidt.;Anders Junker.;Christian Juhl Terkelsen.;Steffen Christensen.;Axel Linke.;Jacob Eifer Møller.;Christian Hassager.; .
来源: Circ Cardiovasc Interv. 2026年19卷3期e015718页
Microaxial flow pump (mAFP) use in selected patients with ST-segment-elevation myocardial infarction complicated by cardiogenic shock improves survival. The present study aimed to assess the influence of delay from first symptoms to randomization on the benefit of an mAFP in patients with ST-segment-elevation myocardial infarction complicated by cardiogenic shock.
33. Prognostic Implications of Evolving Universal Definitions of Periprocedural Myocardial Infarction in Patients With Acute Coronary Syndrome.
作者: Sergio Leonardi.;Antonio Landi.;Andrea Zito.;Mattia Branca.;Enrico Frigoli.;Giuseppe Ando'.;Carlo Briguori.;Paolo Calabro.;Andrea Gagnor.;Roberto Garbo.;Dik Heg.;Ugo Limbruno.;Andrea Milzi.;Elmir Omerovic.;Filippo Russo.;Manel Sabaté.;Andrea Santarelli.;Gennaro Sardella.;Paolo Tosi.;Arnoud W J Van't Hof.;Pascal Vranckx.;Marco Valgimigli.
来源: Circulation. 2026年153卷4期230-242页
The universal definition of percutaneous coronary intervention (PCI)-related myocardial infarction (MI) has been substantially updated over the years, including an increase in the biomarker threshold (from 3 to 5 times the upper reference limit) and the introduction of ancillary criteria such as ischemic symptoms and electrocardiographic or angiographic complication. The impact of these changes in patients with acute coronary syndrome (ACS) remains incompletely understood. The objective of this study was to compare prognostic implications of evolving universal definitions of PCI-MI in a large cohort of patients with ACS from the MATRIX trial (Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of AngioX).
34. Artificial Intelligence-Enabled Echocardiography as a Surrogate for Multimodality Aortic Stenosis Imaging: Post Hoc Analysis of a Clinical Trial.
作者: Evangelos K Oikonomou.;Neil J Craig.;Gregory Holste.;Sumukh Vasisht Shankar.;Audrey C White.;Menaka Mahendran.;David E Newby.;Marc R Dweck.;Rohan Khera.
来源: Circ Cardiovasc Imaging. 2026年19卷2期e018353页
Accurate aortic stenosis (AS) phenotyping requires multimodality imaging which has limited availability. The digital aortic stenosis severity index (DASSi), an artificial intelligence biomarker of AS-related remodeling on single-view 2-dimensional echocardiography, predicts AS progression independent of Doppler measurements. We sought to evaluate the ability of DASSi to define personalized AS progression profiles and to validate its performance as a scalable alternative to multimodality imaging features of functional, structural, and biological AS severity.
35. Heart Failure Risk and Events in People With HIV: The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).
作者: Gerald S Bloomfield.;Maya Watanabe.;Sara McCallum.;Judith A Aberg.;Aya Awwad.;Thomas B Campbell.;Michelle S Cespedes.;Sarah M Chu.;Judith S Currier.;Marissa R Diggs.;Craig A Sponseller.;Carl J Fichtenbaum.;Michael T Lu.;Carlos D Malvestutto.;Gerald Pierone.;Frank Rhame.;Jessica Tuan.;Sophia Zhao.;Markella V Zanni.;Steven K Grinspoon.;Heather J Ribaudo.;Pamela S Douglas.
来源: Circ Heart Fail. 2026年19卷4期e013382页
People with HIV (PWH) may have a higher risk of heart failure (HF) due to traditional and HIV-related factors. Incidence and risk prediction of HF in PWH are not well characterized. We aimed to quantify the risk of HF events in a global population of PWH with low-to-moderate estimated atherosclerotic cardiovascular disease risk.
36. 4D Digital Heart Model-Guided Left and Right Ventricular Lead Placement for Cardiac Resynchronization Therapy: Results of MAPIT-CRT Trial.
作者: Derek S Chew.;Bert Vandenberk.;Derek V Exner.;Dina Labib.;Jacqueline Flewitt.;Yoko Mikami.;Sandra Rivest.;Denise Chan.;Jaimie Manlucu.;Peter Leong-Sit.;Claus Rinne.;David H Birnie.;Pablo B Nery.;Glen Sumner.;Félix Ayala-Paredes.;François Philippon.;Raymond Yee.;James A White.
来源: Circ Arrhythm Electrophysiol. 2026年19卷1期e014132页
Suboptimal left ventricular (LV) and right ventricular lead positioning has been associated with a lesser response to cardiac resynchronization therapy. The MAPIT-CRT (MRI Allocation of Pacing Targets in Cardiac Resynchronization Therapy) randomized controlled trial evaluated a novel, cardiac magnetic resonance-generated 4-dimensional phenomics cardiac magnetic resonance imaging (4DPcmr) lead placement strategy.
37. Resolution of Systemic Inflammation in Patients With Recently Decompensated Heart Failure With Reduced Ejection Fraction With and Without Interleukin-1 Blockade by Anakinra.
作者: Benjamin W Van Tassell.;Michele Golino.;Justin M Canada.;Roshanak Markley.;Hayley Billingsley.;Marco Giuseppe Del Buono.;Azita Talasaz.;Georgia Thomas.;Juan Guido Chiabrando.;George Wohlford.;Virginia Dickson.;Dinesh Kadariya.;Juan Ignacio Damonte.;Ai-Chen Jane Ho.;Yub Raj Sedhai.;Emily Kontos.;Alessandra Vecchiè.;Joshua D West.;Giuliana Corna.;Horacio Medina de Chazal.;Sebastian Pinel.;Edoardo Bressi.;Andrew Barron.;Megan Dell.;James Mbualungu.;Francesco Moroni.;Jeremy Turlington.;Emily Federmann.;Cory R Trankle.;Salvatore Carbone.;Ross Arena.;Antonio Abbate.
来源: Circ Heart Fail. 2026年19卷3期e013546页
Decompensated heart failure with reduced ejection fraction (HFrEF) is associated with systemic inflammation that predicts unfavorable outcomes. We aimed to determine whether anakinra, an IL-1 (interleukin-1) blocker, favors inflammation resolution (CRP [C-reactive protein]) and improves peak oxygen consumption (VO2) in patients with recently decompensated HFrEF.
38. Digital Platform to Optimize Guideline-Directed Heart Failure Therapy: Results of the AIM-POWER Trial.
作者: Adam D DeVore.;Maulik Majmudar.;Leigh Etters.;Jiecheng Xie.;Chen Hao.;Phillip H Lam.;Adrian F Hernandez.;Gregg C Fonarow.;Akshay S Desai.
来源: Circ Heart Fail. 2026年19卷2期e013231页
Less than 1 in 3 patients in the United States with heart failure (HF) with reduced ejection fraction are receiving guideline-recommended medical therapy. Remote titration programs outside of structured episodes of care may address this issue and improve the implementation of guideline-recommended care.
39. Physical Exercise or Cognitive Behavioral Therapy for Takotsubo Cardiomyopathy: A Randomized Controlled Trial.
作者: David T Gamble.;James Ross.;Hilal Khan.;Lesley Cheyne.;Amelia Rudd.;Janaki Srivanasan.;Graham Horgan.;Duncan Hogg.;Phyo K Myint.;David E Newby.;Christopher Williams.;Stuart R Gray.;Dana Dawson.
来源: Circ Heart Fail. 2026年19卷3期e013229页
Takotsubo cardiomyopathy is an acute cardiac emergency presenting with severe left ventricular dysfunction. Physical exercise training or cognitive behavioral therapy may enhance myocardial recovery after takotsubo cardiomyopathy.
40. Calcium Modification After Orbital Atherectomy and Balloon Angioplasty in Severely Calcified Lesions: The ECLIPSE OCT Substudy.
作者: Akiko Maehara.;Ajay J Kirtane.;Philippe Généreux.;Mitsuaki Matsumura.;Bruce E Lewis.;Richard A Shlofmitz.;Suhail Dohad.;Jithendra Choudary.;Thom Dahle.;Andres M Pineda.;Kendrick A Shunk.;Alexandra Popma.;Bjorn Redfors.;Ziad A Ali.;Mitchell W Krucoff.;Ehrin J Armstrong.;David E Kandzari.;Kanitha Phalakornkule.;Carlye Kraemer.;Krista M Stiefel.;Denise E Jones.;Jana R Buccola.;Jeffrey W Chambers.;Gregg W Stone.
来源: Circ Cardiovasc Interv. 2026年19卷1期e015588页
The treatment of calcified coronary lesions requires optimal lesion preparation to achieve a larger minimal stent area (MSA), the strongest predictor of long-term outcomes. The comparative mechanisms of action of calcium-modifying therapies have not been well defined.
|